(R)-(+)-HA-966 ((+)-HA-966; 10 mg/kg; IV) significantly attenuates the dose-dependent pressor response and the associated tachycardic response elicited by systemic NMDA (125, 250, 500, and 1000 mg/kg; i.v.)[3].
(+)-HA-966 (30, 100 mg/kg; IP) dose-dependently blocks the enhancement of dopamine synthesis induced in the nucleus accumbens by amphetamine, but is without effect on the increase in dopamine synthesis in the striatum in male BKTO mice (20-30g)[1].
| Animal Model: | Sprague-Dawley rats (11 to 12 weeks old)[3] |
| Dosage: | 10 mg/kg |
| Administration: | IV |
| Result: | Significantly attenuated the dose-dependent pressor response and the associated tachycardic response elicited by systemic NMDA.
|
